Derazantinib(ARQ-087)

Catalog No.S8609

For research use only.

Derazantinib(ARQ-087) is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with IC50 values of 1.8 nM for FGFR2, and 4.5 nM for FGFR1 and 3, showing lower potency for FGFR4 (IC50=34 nM). It also inhibits RET, DDR2, PDGFRβ, VEGFR and KIT.

Derazantinib(ARQ-087) Chemical Structure

CAS No. 1234356-69-4

Purity & Quality Control

Choose Selective FGFR Inhibitors

Other FGFR Products

Biological Activity

Description Derazantinib(ARQ-087) is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with IC50 values of 1.8 nM for FGFR2, and 4.5 nM for FGFR1 and 3, showing lower potency for FGFR4 (IC50=34 nM). It also inhibits RET, DDR2, PDGFRβ, VEGFR and KIT.
Targets
FGFR2 [1]
(Cell-free assay)
RET [1]
(Cell-free assay)
DDR2 [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
Click to View More Targets
1.8 nM 3 nM 3.6 nM 4.1 nM 4.1 nM
In vitro

ARQ-087 has anti-proliferative activity in cell lines driven by FGFR dysregulation, including amplifications, fusions, and mutations. Cell cycle studies in cell lines with high levels of FGFR2 protein show a positive relationship between ARQ 087 induced G1 cell cycle arrest and subsequent induction of apoptosis. ARQ 087 inhibits the auto-phosphorylation of FGFR1 and FGFR2 in a dose-dependent manner. In Cos-1 cells overexpressing full-length FGFR1, FGFR2, FGFR3 and FGFR4, ARQ 087 inhibits their phosphorylation with EC50 values of < 0.123 μM, 0.185 μM, 0.463 μM, >10 μM respectively. ARQ 087 inhibits FGFR kinase by an ATP competitive mechanism, and is capable of inhibiting both the inactive and fully active forms of the FGFR kinase. Hence, ARQ 087 delays FGFR activation by inhibiting its autophosphorylation, as well as inhibition of the phosphorylated active kinase[1].

In vivo

ARQ 087 attenuates FGFR signaling in SNU-16 human xenograft tumors, leading to a reduction in phospho-FGFR, phospho-FRS2-α, and phospho-ERK, while the total FGFR2 protein is unaffecte. ARQ 087 is effective at inhibiting tumor growth in vivo in FGFR2 altered, SNU-16 and NCI-H716, xenograft tumor models with gene amplifications and fusions. ARQ 087 demonstrated efficacy in multiple in vivo xenograft models, and was well tolerated at doses up to 75 mg/kg[1].

Protocol (from reference)

Kinase Assay:

[1]

  • Determination of Ki and mode of inhibition:

    Kinase inhibitory activity of ARQ 087 was determined for the recombinant FGFR1 or FGFR2 proteins utilizing a biotinylated PYK2 peptide substrate and ATP. ARQ 087 was titrated in DMSO utilizing a 3-fold dilution scheme, and then diluted 10-fold further in deionized water for a final DMSO concentration of 10%. A volume (2.5 μL) of these dilutions or vehicle was added to each well of a reaction plate. FGFR1 or FGFR2 was added to assay buffer (50 mM Tris, pH 8.0, 0.02 mg/mL BSA, 10 mM MgCl2, 1 mM EGTA, 10% glycerol, 0.1 mM Na3PO4, 1 mM DTT) to each well in a volume of 17.5 μL for a final concentration of 0.50 or 0.25 nM, respectively. After a 30-minute pre-incubation period, ATP and substrate were added in assay buffer (5 μL) for final concentrations of 0–1,000 μM ATP and 80 nM biotinylated-PYK2, for a final reaction volume of 25 μL. The plates were incubated for 60 minutes at room temperature, and then stopped in the dark by the addition of 10 μL stop/detection mixture prepared in assay buffer containing EDTA, AlphaScreen™ Streptavidin Donor and P-TYR-100 Acceptor beads for final concentrations of 10 mM EDTA and 500 ng/well of both AlphaScreen™ Donor and Acceptor beads. Assay plates were incubated for 60 minutes at room temperature in the dark, and the plates were read on a Perkin Elmer, Envision Multilabel plate reader. (excitation wavelength: 640 nm, emission wavelength: 570 nm). The effect of enzyme concentration was applied for tight-binding inhibitors, and if necessary, the IC50 values were converted into Ki values if the enzyme concentration was above the IC50 values under the assay conditions utilized.

Cell Research:

[1]

  • Cell lines: NCI-H716 and SNU-16 cells
  • Concentrations: 0.1 μM or 1 μM
  • Incubation Time: 24 or 72 hours
  • Method:

    Cells are plated and incubated at 37°C overnight and subsequently treated with 0.1 μM or 1 μM of ARQ 087 for 24 or 72 hours. The cells were fixed and stained with Cycletest Plus Reagent kit and cell cycle profiles were analyzed using a FACS Calibur flow cytometer.

Animal Research:

[1]

  • Animal Models: female NCr nu/nu mice (SNU-16) or CB17 SCID mice (NCI-H716)
  • Dosages: 0, 25, 50, and 75 mg/kg
  • Administration: oral administration

Solubility (25°C)

In vitro

DMSO 93 mg/mL
(198.47 mM)
Water Insoluble
Ethanol Insoluble

Chemical Information

Molecular Weight 468.57
Formula

C29H29FN4O

CAS No. 1234356-69-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COCCNCCC1=CC(=CC=C1)NC2=NC=C3CC(C4=CC=CC=C4C3=N2)C5=CC=CC=C5F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03230318 Recruiting Drug: derazantinib Intrahepatic Cholangiocarcinoma|Combined Hepatocellular and Cholangiocarcinoma Basilea Pharmaceutica November 10 2017 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Derazantinib(ARQ-087) | Derazantinib(ARQ-087) supplier | purchase Derazantinib(ARQ-087) | Derazantinib(ARQ-087) cost | Derazantinib(ARQ-087) manufacturer | order Derazantinib(ARQ-087) | Derazantinib(ARQ-087) distributor